Lv5
860 积分 2021-07-18 加入
Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes
4天前
已完结
Hepatocyte DDIT4 aggravates MASH progression through GPX4-mediated ferroptosis
29天前
已关闭
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
1个月前
已完结
Effect of Diactive-1 mHealth-Supported Progressive Resistance Training on Insulin Requirements, Glycemic Stability, and Muscular Strength in Children and Adolescents With Type 1 Diabetes: A Parallel-Group Randomized Controlled Trial
1个月前
已完结
Effects of Interventions for Improving Awareness and Knowledge of Nonalcoholic Fatty Liver Disease Among Chinese Young Adults for Prevention of Liver Cancer—A Randomized Controlled Trial
1个月前
已完结
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
1个月前
已完结
GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials
1个月前
已完结
Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database
1个月前
已关闭
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
1个月前
已完结
Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
1个月前
已完结
皖公网安备34019202002308
